[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614859":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":34,"responsibleParty":113,"collaborators":11,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":117,"sex":123,"minAge":124,"maxAge":11,"enrollmentInfo":125,"targetDuration":11,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Novaliq GmbH","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tacrolimus ophthalmic solution (high dose)","ACTIVE_COMPARATOR",null,[13],"Drug: Tacrolimus ophthalmic solution",{"label":15,"type":10,"description":11,"interventionNames":16},"Tacrolimus ophthalmic solution (low dose)",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Tacrolimus ophthalmic solution","high and low dose treatment will be compared over 6 weeks treatment",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Sonja Kroesser, PhD","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Alice Meides, PhD","CONTACT","+49 622150259","0","ameides@novaliq.com",[35,54,69,84,99],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Bascom Palmer Eye Institute","RECRUITING","Miami","Florida","33136","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-80.19366,25.77427,{"lat":47,"lon":46},[50],{"name":51,"role":30,"phone":52,"phoneExt":11,"email":53},"Javier Paredes","305-326-6387","jxp2537@med.miami.edu",{"facility":55,"status":37,"city":56,"state":57,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Massachusetts Eye Research and Surgery Institution","Waltham","Massachusetts","02451",{"type":44,"coordinates":60},[61,62],-71.23561,42.37649,{"lat":62,"lon":61},[65],{"name":66,"role":30,"phone":67,"phoneExt":68,"email":11},"Megan Mitchell","+1 781-647-1431","402",{"facility":70,"status":37,"city":71,"state":72,"zip":73,"country":41,"countryCode":42,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Metropolitan Eye Research and Surgery Institute","Palisades Park","New Jersey","07650",{"type":44,"coordinates":75},[76,77],-73.99764,40.84816,{"lat":77,"lon":76},[80],{"name":81,"role":30,"phone":82,"phoneExt":83,"email":11},"Sachi Desai","+1 201-461-3970","125",{"facility":85,"status":37,"city":86,"state":87,"zip":88,"country":41,"countryCode":42,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Valley Retina Institute, P.A.","McAllen","Texas","78503",{"type":44,"coordinates":90},[91,92],-98.23001,26.20341,{"lat":92,"lon":91},[95],{"name":96,"role":30,"phone":97,"phoneExt":98,"email":11},"Alexia Salas","+1 956-631-8875","1802",{"facility":100,"status":37,"city":101,"state":102,"zip":103,"country":41,"countryCode":42,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Virginia Eye Consultants","Norfolk","Virginia","23502",{"type":44,"coordinates":105},[106,107],-76.28522,36.84681,{"lat":107,"lon":106},[110],{"name":111,"role":30,"phone":112,"phoneExt":11,"email":11},"Alexandria Robinson","+1 757-493-3053",{"type":114,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614859","phase-2-tacrolimus-ophthalmic-solution-for-the-treatment-of-non-infectious-anterior-uveitis-100614859",false,"NCT07285070","Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis","A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05) for the Treatment of Non-Infectious Anterior Uveitis","EYETAC","Inclusion Criteria:\n\n* Be ≥18 years of age;\n* Provide written informed consent;\n* Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation;\n* Have an onset of symptoms within 4 weeks;\n\nExclusion Criteria:\n\n* Have severe\u002Fserious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator;\n* Have a history of or a current ocular or periocular malignancy;\n* Have active intermediate or posterior uveitis in the study eye or another documented posterior segment inflammation;\n* A confirmed or highly suspicious infectious uveitis eg, CMV, Herpes simplex, Herpes zoster, syphilis, tuberculosis, lyme disease;\n* Have a known allergy or sensitivity to the IMP tacrolimus or semifluorinated alkanes (SFA);\n* Be a woman who is pregnant, nursing, or planning a pregnancy;\n* Have a condition or be in a situation (e.g. language barrier, non-cooperative, history of substance abuse) which the Investigator considers that it may put the patient at significant risk, may confound the trial results, or may significantly interfere with the patient's participation in the trial;","ALL","18 Years",{"count":126,"type":127},20,"ESTIMATED","INTERVENTIONAL",[130],"PHASE2","The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.",[133],"Non-infectious Anterior Uveitis","2026-06-12",{"date":136,"type":137},"2026-06-15","ACTUAL",{"date":139,"type":137},"2026-03-16",{"date":141,"type":127},"2026-10",{"name":5,"class":6},5]